Reactions 1680, p263 - 2 Dec 2017
Thrombocytopenia: case report
In a retrospective cohort analysis of 167 patients, a patient
[age and sex not stated] was described, who developed
thrombocytopenia during treatment with octreotate-
Lu-DOTATATE; duration of treatment
to reaction onset not stated].
The patient, who had advanced neuroendocrine tumour,
received treatment with 5550 to 7400 MBq (150
200 mCi) of
octreotate-Lu-177-DOTA-Tyr-3 diluted in 48 to 50mL of
sodium chloride [saline] and infused over 30 minutes with a
flow rate of 1.6 mL/minute. The patient received octreotate-
Lu-177-DOTA-Tyr-3 after 30 to 60 minutes from the start of
amino acid infusion. Before the initiation of treatment, the
patient had grade I thrombocytopenia. However, during the
course of therapy, the patient exhibited further depletion in the
platelet counts (86000
48000 /µL), which was considered as
grade III thrombocytopenia.
The patient’s decreased platelet count was managed with
Author comment: "Treatment-related adverse events were
analyzed in all the patients." "One patient presented with
grade I thrombocytopenia at the time of recruitment and
progressed to grade III toxicity." "The platelet counts in this
patient were revived through platelet transfusion."
Ballal S, et al. Concomitant 177Lu-DOTATATE and Capecitabine Therapy in
Patients with Advanced Neuroendocrine Tumors: A Long-term-Outcome, Toxicity,
Survival, and Quality-of-Life Study. Clinical Nuclear Medicine 42: e457-e466, No.
11, Nov 2017. Available from: URL: http://doi.org/10.1097/
RLU.0000000000001816 - India
Reactions 2 Dec 2017 No. 16800114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved